FY2021 · ended Dec 31, 2021 · Revenue $0 · Filed Mar 31, 2023
Instil Bio, Inc. (TIL) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $69.7 million in cash and investments and $2.2 million in total debt.
Revenue
$0
Net income
$-71.37M
+3.7% vs prior year
Operating cash flow (TTM)
$-23.61M
+52.5% vs year-ago TTM
Free cash flow
$-55.70M
+45.8% vs prior year
EPS
$-10.70
+6.1% vs prior year
Dividend per share
None
Shares outstanding
6.78M
+3.9% vs prior year
Net cash
$67.45M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TIL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NY
- Headquarters
- Dallas, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1789769
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 |
| Operating income | -$78.6M | -$73.5M | -$159.2M | -$226.5M | -$155.6M |
| Net income | -$71.4M | -$74.1M | -$156.1M | -$223.2M | -$156.8M |
| Diluted EPS | -$10.70 | -$11.39 | -$24.00 | -$34.46 | -$1.48 |
| Operating cash flow | -$36.6M | -$55.7M | -$82.0M | -$180.2M | -$122.1M |
| Free cash flow | — | -$55.7M | -$102.7M | -$264.8M | -$180.0M |
| Total assets | $203.5M | $263.6M | $325.6M | $482.1M | $610.0M |
| Total liabilities | $89.7M | $94.1M | $99.8M | $118.5M | $54.8M |
| Stockholders' equity | $113.9M | $169.4M | $225.8M | $363.6M | $555.2M |
| Cash and investments | $76.1M | $8.8M | $173.5M | $260.9M | $454.1M |
| Total debt | $372,000 | $2.7M | $4.6M | $7.6M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 11, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 15, 2026 | May 15, 2026 |
| ARS | Annual report to shareholders | Apr 24, 2026 | Dec 31, 2025 |
All 248 Instil Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.